Nonresearch Pharmaceutical Industry Payments to Oncology Physician Editors
Open Access
- 1 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (6), E986-E989
- https://doi.org/10.1634/theoncologist.2019-0828
Abstract
Journal editors are gatekeepers of knowledge, and pharmaceutical industry payments to oncology editors have not been previously characterized. We performed a cross-sectional study of nonresearch industry payments to editors of 26 oncology research journals. A total of 433 editors were eligible for inclusion in the CMS Open Payments database from 2013 to 2018. A total of 80% of eligible editors had nonresearch payments, and the mean value of payments per editor was $106,778, which has increased over time. Only 5 out of 26 journals disclosed editor conflicts of interest and 3 of these journals reported at least one editor with no nonresearch industry payments but were found to have nonresearch payments. There was a positive correlation between journal impact factor and the average payment per editor for each journal. Our study shows the high prevalence and lack of transparency of nonresearch industry payments to oncology editors. Higher impact journals appear to be associated with greater nonresearch industry payments.This publication has 8 references indexed in Scilit:
- Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare BeneficiariesJAMA Internal Medicine, 2018
- Conflicts of interest of editors of medical journalsPLOS ONE, 2018
- Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational studyBMJ, 2017
- Distribution and Patterns of Industry-Related Payments to Oncologists in 2014JNCI Journal of the National Cancer Institute, 2016
- Effects of a Novel Long Noncoding RNA, lncUSMycN, on N-Myc Expression and Neuroblastoma ProgressionJNCI Journal of the National Cancer Institute, 2014
- A Randomized Study of How Physicians Interpret Research Funding DisclosuresThe New England Journal of Medicine, 2012
- The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trialsContemporary Clinical Trials, 2012
- Surviving Sepsis — Practice Guidelines, Marketing Campaigns, and Eli LillyThe New England Journal of Medicine, 2006